The Drug Regulatory Authority of Pakistan (DRAP) operates the National Pharmacovigilance Centre (NPC).
Core official resources
- Pharmacovigilance guidelines — national system guidance, Good Pharmacovigilance Practices for registration holders and industry e-reporting material.
- Adverse Events Reporting — current reporter and industry reporting routes.
Important national distinction
DRAP currently identifies Med Vigilance electronic reporting for patients and healthcare professionals. For industry, DRAP states that E2B XML submission to the National Pharmacovigilance Centre is the routine procedure, with CIOMS submission retained as an alternative for registration holders that cannot yet generate E2B XML.